oncology treatment

Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL

INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...

By cGxPwire Editor
September 8, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

oncology treatment

Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL